CO2019011604A2 - Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos - Google Patents

Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos

Info

Publication number
CO2019011604A2
CO2019011604A2 CO2019011604A CO2019011604A CO2019011604A2 CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2 CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2
Authority
CO
Colombia
Prior art keywords
methods relating
compositions
compounds
inhibitor compounds
vmat2 inhibitor
Prior art date
Application number
CO2019011604A
Other languages
English (en)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019011604(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CO2019011604A2 publication Critical patent/CO2019011604A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto seleccionado de compuestos de fórmula (I) y sales, solvatos e hidratos farmacéuticamente aceptables de los mismos: (I) en la que R1, R2, R3 y R4 son tal como se definen en el presente documento. Tales compuestos son inhibidores del transportador vesicular de monoaminas 2 (VMAT2) y tienen utilidad para tratar, por ejemplo, enfermedades y trastornos neurológicos y psiquiátricos. También se dan a conocer composiciones que contienen tales compuestos en combinación con un portador farmacéuticamente aceptable, así como métodos relativos a su uso en sujetos que lo necesitan.
CO2019011604A 2017-04-19 2019-10-18 Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos CO2019011604A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (1)

Publication Number Publication Date
CO2019011604A2 true CO2019011604A2 (es) 2019-10-31

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
CO2019011604A CO2019011604A2 (es) 2017-04-19 2019-10-18 Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos

Country Status (16)

Country Link
US (1) US11040970B2 (es)
EP (1) EP3612532B1 (es)
JP (1) JP7170662B2 (es)
KR (1) KR20190140968A (es)
CN (1) CN110770236B (es)
AU (1) AU2018254429A1 (es)
BR (1) BR112019021853A2 (es)
CA (1) CA3060251A1 (es)
CL (1) CL2019002919A1 (es)
CO (1) CO2019011604A2 (es)
JO (1) JOP20190239A1 (es)
MA (1) MA50145A (es)
MX (1) MX2019012336A (es)
PE (1) PE20191784A1 (es)
TW (1) TW201841913A (es)
WO (1) WO2018195121A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
SG11202011544UA (en) * 2018-06-14 2020-12-30 Neurocrine Biosciences Inc Vmat2 inhibitor compounds, compositions, and methods relating thereto
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
WO2022203984A1 (en) 2021-03-22 2022-09-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
CA2528784C (en) 2003-06-20 2012-02-21 Markus Boehringer Hexahydropyridoisoquinolines as dpp-iv inhibitors
US20060035883A1 (en) * 2004-08-13 2006-02-16 Tedford Clark E Novel serotonin receptor ligands and their uses thereof
EA018378B1 (ru) 2006-11-08 2013-07-30 Ньюрокрайн Байосайенсиз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9012471B2 (en) * 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2784830C (en) * 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
EP2835372B1 (en) 2012-09-19 2016-05-04 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Thiophene [2, 3-d]pyrimidine derivative, and preparation method and use thereof
EP4049681A1 (en) 2014-02-07 2022-08-31 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
NZ733899A (en) * 2015-02-06 2024-01-26 Neurocrine Biosciences Inc [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores

Also Published As

Publication number Publication date
AU2018254429A1 (en) 2019-11-07
CA3060251A1 (en) 2018-10-25
CN110770236B (zh) 2023-03-24
MX2019012336A (es) 2020-07-14
JOP20190239A1 (ar) 2019-10-09
PE20191784A1 (es) 2019-12-24
JP7170662B2 (ja) 2022-11-14
BR112019021853A2 (pt) 2020-05-26
KR20190140968A (ko) 2019-12-20
CN110770236A (zh) 2020-02-07
WO2018195121A1 (en) 2018-10-25
MA50145A (fr) 2020-07-29
EP3612532B1 (en) 2023-12-13
US20200131173A1 (en) 2020-04-30
JP2020517607A (ja) 2020-06-18
EP3612532C0 (en) 2023-12-13
CL2019002919A1 (es) 2020-01-17
EP3612532A1 (en) 2020-02-26
TW201841913A (zh) 2018-12-01
US11040970B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
NZ733899A (en) [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
MY177574A (en) New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
ECSP109958A (es) Derivados de pirimidina 934
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
AR117835A1 (es) Complejo diastereoisomérico enriquecido de gadolinio y de un ligando quelante a base de pcta, y proceso de preparación y purificación del mismo
PE20171348A1 (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
CO6241116A2 (es) Pirimidil piperazinas utiles como ligandos del receptor d3/d2
CO2020016080A2 (es) Compuestos
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR099071A1 (es) Antagonistas selectivos de nr2b
CO2017011511A2 (es) Derivados de indol
CU20130065A7 (es) Derivados de indol